XNCR
HOLD / NEUTRALNeutralComposite
47.00
Technical
96.20
Fundamental
14.20
Rank
—
Price
27.27
Hurst
0.44
As of
Sep 1, 2026
Daily
Xencor, Inc.
HealthcareBiotechnologyXencor, Inc. is a biopharmaceutical company developing engineered antibodies for cancer and autoimmune disease treatment. The company has marketed therapies including Ultomiris for hemolytic uremic syndrome and myasthenia gravis, and Monjuvi for certain lymphomas, while maintaining a pipeline of experimental bispecific antibodies and other immunotherapies targeting various malignancies and inflammatory conditions. Headquartered in Pasadena, California, the company was founded in 1997.
Market cap
$2.2B
P/E (trailing)
—
P/E (forward)
-8.43
PEG ratio
—
Dividend yield
0.00%
Beta
0.90
52w range
10.38 – 33.60
Return on equity
-29.07%
Profit margin
-155.59%
Revenue growth
+17.50%
Earnings growth
—
Price history
1Y: 29.82 (+102.7%) · range 10.41–29.99
Cycle position
84/ 100 cycle scoreEXIT ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 0 · NOT READY · exit proximity 58
Conviction
25/ 100 · maturity 29%
VScore.1614
Buildup.2870
EMA entry setup.350
Fundamentals.2114
Volume profile
POC
24.54
Price vs POC
+21.5%
Overhead supply
7%
Runway
open sky
Value area 18.74–31.74 · 7% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trend-signal | 0.097 | Oct 27, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -10.61% | -3.62% | mature |
| 40d | -9.78% | -3.62% | 37/40d |